Yesterday it was reported that the EVP, CFO & CBO of Sarepta Therapeutics (SRPT), Sandesh Mahatme, exercised options to buy 9,754 SRPT shares at $24.73 a share, for a total transaction value of $241.2K.
Following Sandesh Mahatme’s last SRPT Buy transaction on November 10, 2016, the stock climbed by 81.0%. Following this transaction Sandesh Mahatme’s holding in the company was increased by 38.18% to a total of $5.15 million.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $94.67 million and GAAP net loss of $276 million. In comparison, last year the company earned revenue of $73.53 million and had a GAAP net loss of $109 million. The company has a one-year high of $165.87 and a one-year low of $95.21. Currently, Sarepta Therapeutics has an average volume of 962.75K.
Starting in May 2019, SRPT received 32 Buy ratings in a row. 15 different firms, including Merrill Lynch and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Sarepta Therapeutics has been positive according to 32 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Sandesh Mahatme’s trades have generated a -0.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.